XtalPi and PhoreMost Sign Pharmaceutical Drug Discovery Collaboration Agreement

Using XtalPi's ID4 platform, the companies will discover drug candidates for "undruggable" targets
Learn More

Fundamentals of Solid Formulation

April 6, 13, 20, 27 | 11:00 AM – Noon EDT
Learn More

Building an AI-powered Drug R&D Engine

to empower pharmaceutical research with increased efficiency and success rate.
Learn More

AI Drug R&D Startup XtalPi Announces Over 300 Million Series C Investment

Led by SoftBank Vision Fund, PICC Capital, and Morningside
Learn More

How Quantum Physics and AI is Disrupting Drug Discovery & Development

Case study on how XtalPi is helping Pfizer scientists predict and optimize the crystalline forms of drug candidates.
Learn More

XtalPi and PhoreMost Sign Pharmaceutical Drug Discovery Collaboration Agreement

Using XtalPi's ID4 platform, the companies will discover drug candidates for "undruggable" targets
Learn More

Fundamentals of Solid Formulation

April 6, 13, 20, 27 | 11:00 AM – Noon EDT
Learn More

Drug Discovery

Combining AI and computational chemistry, we developed a series of innovative methods to address challenging drug discovery and design tasks, including molecular structure generation, binding affinity prediction, and key drug property predictions. Based on these AI-empowered capabilities, we are working with industry partners in the one-stop drug discovery of small molecules and macromolecule services, to improve research efficiency, reduce costs, and increase the overall success rate of innovative therapeutics in R&D.

Small Molecule Drug Discovery

Our integrated drug research platform focuses on hit identification and lead optimization to produce high-quality pre-clinical candidate molecules. Our workflow is empowered by AI computation, wet lab experimentation and research experience in medicinal chemistry. Our work scope is comprehensive and includes molecule generation, evaluation on drug-like properties and optimization, ADMET properties prediction, chemical synthesis and biological functional studies. Leveraging our platform, we aspire to revolutionize the classical methods for drug discovery and development by improving the speed, scale, novelty and diversity for pharmaceutical innovations in China and around the world.

Macromolecule Drug Discovery

Comprised of experts in protein science, biochemistry, biophysics, medicinal and computational chemistry, and discovery scientists with expertise in pre-clinical development, our drug R&D team is applying the integrated technology platform-based approach and our practical expertise across a portfolio of internal and external drug discovery programs spanning across a wide range of disease targets and indications. We continue to develop and expand our research capabilities in other drug modalities, including antibodies and RNAs.

One-stop Drug Discovery

Deploying our integrated technology platform, we provide one-stop drug discovery services. The services generally cover developmental stages from early hit generation to IND-enabling studies for the initiation of Phase I clinical trials. In addition to one-stop drug discovery services, we establish drug discovery collaborations with drug developers. With our industry-leading, AI-powered capabilities and practical experience, we are able to assist our customers and collaborators to tackle problems efficiently in early drug discovery and development and to conduct discovery of novel therapeutics at a pace and scale beyond those with the traditional wet lab-based approaches.

Contact us
banner
FUNDAMENTALS OF SOLID FORMULATION
Finished
June 16, 2020-July 29, 2020
online
View Event
...
Fierce Medtech names XtalPi as one of its “Fierce 15” Med Tech Companies of 2021

Named as one of the most promising private med-tech companies in the industry

...
XtalPi and Signet Expand AI Drug Discovery Collaboration to Novel Cancer Target

Expanding the tried-and-true "AI drug discovery + novel organoid disease models" paradigm to new cancer drug pipeline collaboration

...
Research Collaboration between XtalPi Inc and Acerand Therapeutics to develop potential novel anti-cancer therapies using High-precision Physics-based model and Machine Learning

The partnership will leverage XtalPi’s highly accurate physics-based models and machine learning models to develop potential novel chemical entities for a cancer target.

View News